Data / Drug companies / Desvenlafaxine
Desvenlafaxine: 14 companies and 37 products in the FDA NDC directory
Desvenlafaxine is listed in the FDA National Drug Code Directory by 14 companies, with 37 products in commercial distribution. 33 of the products (89.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, extended release; tablet, film coated, extended release, and the newest product started marketing on July 1, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 14
- Products
- 37
- Generic (ANDA) products
- 33 (89.2%)
- Application numbers
- 7
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list desvenlafaxine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 7 | tablet, extended release; tablet, film coated, extended release | Generic drugs (ANDA) | January 31, 2022 |
| A-S Medication Solutions | 4 | tablet, extended release; tablet, film coated, extended release | Generic drugs (ANDA) | January 31, 2022 |
| Actavis Pharma, Inc. | 3 | tablet, extended release | Generic drugs (ANDA) | March 1, 2017 |
| Advagen Pharma Ltd | 3 | tablet, extended release | Generic drugs (ANDA) | January 31, 2022 |
| Hikma Pharmaceuticals USA Inc. | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | August 29, 2017 |
| NorthStar RxLLC | 3 | tablet, extended release | Generic drugs (ANDA) | May 2, 2025 |
| Slate Run Pharmaceuticals, LLC | 3 | tablet, extended release | Generic drugs (ANDA) | January 5, 2021 |
| Alembic Pharmaceuticals Limited | 2 | tablet, extended release | New drug applications (NDA) | March 5, 2013 |
| Marlex Pharmaceuticals, Inc. | 2 | tablet, extended release | Generic drugs (ANDA) | July 1, 2025 |
| NuCare Pharmaceuticals,Inc. | 2 | tablet, extended release | Generic drugs (ANDA) | May 2, 2025 |
| Sun Pharmaceutical Industries, Inc. | 2 | tablet, extended release | New drug applications (NDA) | March 5, 2013 |
| American Health Packaging | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | December 1, 2021 |
| Bryant Ranch Prepack | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | August 29, 2017 |
| Preferred Pharmaceuticals Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | November 11, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 30 | 81.1% |
| Tablet, film coated, extended release | 7 | 18.9% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 33 | 89.2% |
| New drug applications (NDA) | 4 | 10.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Serotonin and Norepinephrine Reuptake Inhibitor | 37 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.